2017
Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial
Arrieta A, Hong JC, Khera R, Virani SS, Krumholz HM, Nasir K. Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial. JAMA Cardiology 2017, 2: 1369-1374. PMID: 29049467, PMCID: PMC5814995, DOI: 10.1001/jamacardio.2017.3655.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnticholesteremic AgentsCardiovascular DiseasesCholesterol, LDLCost-Benefit AnalysisDecision Support TechniquesDrug Therapy, CombinationFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypercholesterolemiaInsuranceInsurance, HealthInsurance, Health, ReimbursementMaleMarkov ChainsMiddle AgedMyocardial InfarctionPCSK9 InhibitorsQuality-Adjusted Life YearsStrokeUnited StatesConceptsQuality-adjusted life yearsIncremental cost-effectiveness ratioCost-effectiveness ratioProprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitorsCurrent pricesLife yearsPrivate payersAdditional quality-adjusted life yearPreliminary cost-effectiveness analysisCost-effectiveness standardsProbabilistic sensitivity analysesCost-effectiveness analysisPrivate payer perspectiveCost-effectiveness assessmentNegative returnsHealth system perspectiveSignificant discountUS dollarsDrug pricesPatent protectionPricesStatin treatment strategiesHealth insuranceTime horizonSubtilisin/kexin type 9 inhibitorsImplications of Coronary Artery Calcium Testing for Treatment Decisions Among Statin Candidates According to the ACC/AHA Cholesterol Management Guidelines A Cost-Effectiveness Analysis
Hong JC, Blankstein R, Shaw LJ, Padula WV, Arrieta A, Fialkow JA, Blumenthal RS, Blaha MJ, Krumholz HM, Nasir K. Implications of Coronary Artery Calcium Testing for Treatment Decisions Among Statin Candidates According to the ACC/AHA Cholesterol Management Guidelines A Cost-Effectiveness Analysis. JACC Cardiovascular Imaging 2017, 10: 938-952. PMID: 28797417, DOI: 10.1016/j.jcmg.2017.04.014.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAmerican Heart AssociationBayes TheoremClinical Decision-MakingComputer SimulationCoronary AngiographyCoronary Artery DiseaseCoronary VesselsCost-Benefit AnalysisDecision Support TechniquesDrug CostsFemaleGuideline AdherenceHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedModels, EconomicMonte Carlo MethodMultivariate AnalysisPractice Guidelines as TopicPredictive Value of TestsQuality of LifeQuality-Adjusted Life YearsTime FactorsTreatment OutcomeUnited StatesVascular CalcificationConceptsCoronary artery calciumQuality-adjusted life yearsStatin therapyArtery calciumLong-term statin therapyAtherosclerotic cardiovascular disease eventsCholesterol management guidelinesIncremental cost-effectiveness ratioCardiovascular disease eventsAtherosclerotic cardiovascular diseaseCost-effectiveness ratioCost-effectiveness analysisStatin candidatesCholesterol managementCardiovascular diseaseTreatment decisionsAmerican CollegeDisease eventsLifetime horizonLife yearsAmerican HeartSocietal perspectiveManagement guidelinesStatinsPatients
1999
Economics, health-related quality of life, and cost-effectiveness methods for the TACTICS (Treat Angina with Aggrastat® [tirofiban] and Determine Cost of Therapy with Invasive or Conservative Strategy)–TIMI 18 trial
Weintraub W, Culler S, Kosinski A, Becker E, Mahoney E, Burnette J, Spertus J, Feeny D, Cohen D, Krumholz H, Ellis S, Demopoulos L, Robertson D, Boccuzzi S, Barr E, Cannon C. Economics, health-related quality of life, and cost-effectiveness methods for the TACTICS (Treat Angina with Aggrastat® [tirofiban] and Determine Cost of Therapy with Invasive or Conservative Strategy)–TIMI 18 trial. The American Journal Of Cardiology 1999, 83: 317-322. PMID: 10072215, DOI: 10.1016/s0002-9149(98)00860-1.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsHealth Utilities IndexLife yearsHealth-related qualityCost-effectiveness methodsNon-Q-wave myocardial infarctionUtility indexCost-effectiveness analysisDetermine CostImpact of invasiveEconomic formsUB92 formulationHealth care costsUnstable anginaRelative value scaleMedicare conversion factorMyocardial infarctionMedicare fee scheduleDepartmental costsEconomicsExpensive formFee scheduleTACTICS-TIMI 18Care costsOutcomes of patients
1995
A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction
Kalish S, Gurwitz J, Krumholz H, Avorn J. A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction. Journal Of General Internal Medicine 1995, 10: 321-330. PMID: 7562123, DOI: 10.1007/bf02599951.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsTissue plasminogen activatorAcute myocardial infarctionAdditional quality-adjusted life yearMyocardial infarctionGUSTO trialThrombolytic therapyOne-year mortality dataOccluded Coronary Arteries (GUSTO-I) trialMortality dataPlasminogen activatorLong-term medical costsCoronary Arteries trialOne-year mortalityUse of streptokinaseInferior wall infarctionCost-effective therapyCost-effectiveness modelDecision analysis modelSurvival benefitSymptom onsetClinical outcomesRelative survival advantageThrombolytic agentsSurvival advantage